Clinical Trials
10 trialsNCT06915766 2026-05-28
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
Cogent Biosciences, Inc.
Available
NCT04910685 2026-05-22
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2/3 Recruiting
NCT05186753 2026-05-22
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cogent Biosciences, Inc.
Phase 2 Active not recruiting
NCT05362773 2026-05-22
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
Phase 1 Recruiting
NCT04996875 2026-05-05
APEX
Cogent Biosciences, Inc.
Phase 2 Recruiting
NCT07562542 2026-05-01
PB-KIT in SM
The First Affiliated Hospital of Soochow University
Recruiting
NCT03580655 2026-04-24
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2 Completed
NCT07264959 2026-04-22
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
Blueprint Medicines Corporation
Recruiting
NCT07255638 2026-04-20
A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
Blueprint Medicines Corporation
Recruiting
NCT03401060 2026-03-31
DenosuMast
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed